Maiken  Keson-Brookes net worth and biography

Maiken Keson-Brookes Biography and Net Worth

Maiken Keson-Brookes joined Rubius as Chief Legal Officer and Corporate Secretary in November 2019, bringing more than 20 years of international legal experience and working biopharmaceutical companies from the discovery phase all the way through commercialization. She oversees Rubius’ legal and securities matters and intellectual property. Maiken joined Rubius from Synlogic, Inc., where she served as general counsel. Prior to Synlogic, she served as senior vice president and general counsel at uniQure, a gene therapy company. Before uniQure, she was senior vice president and general counsel at Forum Pharmaceuticals, where she established the company’s first legal department and built a legal team to support all aspects of the business. Earlier, Maiken held legal roles at Genzyme and Biogen. While with Biogen, she served as attorney for the ex-U.S. launch of several products and provided legal oversight for the company’s manufacturing group, including a large-scale manufacturing facility construction project.

Maiken holds master of laws and bachelor of laws degrees from Kings College University of London.

What is Maiken Keson-Brookes' net worth?

The estimated net worth of Maiken Keson-Brookes is at least $1,425.00 as of March 15th, 2021. Ms. Keson-Brookes owns 25,000 shares of Rubius Therapeutics stock worth more than $1,425 as of March 28th. This net worth evaluation does not reflect any other investments that Ms. Keson-Brookes may own. Learn More about Maiken Keson-Brookes' net worth.

How do I contact Maiken Keson-Brookes?

The corporate mailing address for Ms. Keson-Brookes and other Rubius Therapeutics executives is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. Rubius Therapeutics can also be reached via phone at (508) 543-1720 and via email at [email protected]. Learn More on Maiken Keson-Brookes' contact information.

Has Maiken Keson-Brookes been buying or selling shares of Rubius Therapeutics?

Maiken Keson-Brookes has not been actively trading shares of Rubius Therapeutics during the last ninety days. Most recently, Maiken Keson-Brookes sold 2,732 shares of the business's stock in a transaction on Tuesday, February 1st. The shares were sold at an average price of $6.57, for a transaction totalling $17,949.24. Learn More on Maiken Keson-Brookes' trading history.

Who are Rubius Therapeutics' active insiders?

Rubius Therapeutics' insider roster includes Pablo Cagnoni (CEO), and Maiken Keson-Brookes (Insider). Learn More on Rubius Therapeutics' active insiders.

Maiken Keson-Brookes Insider Trading History at Rubius Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2022Sell2,732$6.57$17,949.24View SEC Filing Icon  
3/15/2021Sell25,000$20.24$506,000.0025,000View SEC Filing Icon  
See Full Table

Maiken Keson-Brookes Buying and Selling Activity at Rubius Therapeutics

This chart shows Maiken Keson-Brookes's buying and selling at Rubius Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rubius Therapeutics Company Overview

Rubius Therapeutics logo
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.
Read More

Today's Range

Now: $0.06
Low: $0.06
High: $0.06

50 Day Range

MA: $0.04
Low: $0.02
High: $0.06

2 Week Range

Now: $0.06
Low: $0.00
High: $0.38

Volume

755,800 shs

Average Volume

1,154,788 shs

Market Capitalization

$5.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.59